Hyperhomocysteinemia in developing age and nutritional aspects of folates: An early cardiovascular risk factor;Iperomocisteinemia in età evolutiva e aspetti nutrizionali dei folati: Un fattore di rischio cardiovascolare precoce

Monaldi Archives for Chest Disease - Cardiac Series

Volumn 66, Issue 4, 2006, Pages 275-285

  Caramia, Giuseppe ^a   Belardinelli, Romualdo ^b  

^a Ospedale Pediatrico G Salesi   (Italy)

^b Clinic Center di Napoli   (Italy)

Author keywords

5 methyltetrahydrofolate; Arteriosclerotic vascular disease; Cardiovascular risk factors; Folic acid; Hyperhomocysteinemia

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE;

ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; EXERCISE; HUMAN; HYPERHOMOCYSTEINEMIA; INCIDENCE; NUTRITIONAL ASSESSMENT; OUTCOME ASSESSMENT; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SUPPLEMENTATION;

EID: 33846952121     PISSN: 11220643     EISSN: None     Source Type: Journal    
DOI: 10.4081/monaldi.2006.519     Document Type: Review

References (78)

1. Rezvani I. Metionina, in Nelson: Trattato di Pediatria. Edizioni Minerva Medica. XVI Ed. 2002; X-82.3: 350-52.
2. Mudd SH, Levy HL, Kraus J. Disorders of Transsulfuration. In: The metabolic & molecolar bases of inherited Diseases VIII Ed. Mc Grow Hill 2001; 88: 2008-48
3. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 561: 11-28.
4. Mudd SH, Skovby R, Levy HL, et al. The natural history of homocystinuria due to cystathionine-Beta-synthase deficiency. Am J Hum Genet 1985; 37: 1-31.
5. Davì G, Di Minno G, Coppola A, et al. Oxidative Stress and Platelet Activation in Homozygous Homocystinuria. Circulation 2001; 104: 1: 124.
6. Sebastio G, Sperandeo MT, Panico M, et al. The molecular basis of homocystinuria due to cysthationine-Beta-synthase deficiency in Italian families and report of four novel mutations. Am J Hum Genet 1995; 56: 1324-33.
7. Coppola A, De Simone C, Coppola D, et al. Omocisteina, folati e patologia tromboembolica. Riv I Ost Gin 2004; 1: 13-19.
8. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-3.
9. de Franchis R, Mancini FR D Angelo A, et al. Elevated total pasma homocysteine and 677→ T mutation of 5, 10-methylenetetrahydrofolate reductase gene in thrombotic vascular disease. Am J Hum Genet 1996; 59: 262-4.
10. D Angelo A, Coppola A, Madonna P, et al. The role of vitamin B12 in fasting hyperhomocysteinemia and its interaction with the homozygous C677T mutation of the methylenetetrahydrofolate reductase (MTHFR) gene. A case-control study of patients with early-onset thrombotic events. Thromb Haemost 2000; 83: 563-70.
11. De Franchis R, Fermo I, Mazzola G, et al. Contribution of the cystathionine beta-synthase gene (844ins68) polymorphism to the risk ofearly-onset venous and arterial occlusi ve disease and offasting hyperhomocysteinemia. Thromb Haemost 2000; 84: 576-82.
12. Meyer K, Fredriksen A, Ueland PM. High-level multiplex genotyping of polymorphisms involved in folate or homocysteine metabolism by matrix-assisted laser desorption/ionization mass spectrometry. Clin Chem 2004; 50: 391-402.
13. Motulsky A. Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects and folic acid. Am J Hum Genet 1996; 58: 17-20.
14. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA 1997; 277: 1775-81.
15. Boushey CJ, Beresford SAA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
16. den Heijer M, Rosendaal FR, Blom HJ et al. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 1998; 80: 874-7.
17. Guttormsen AB, Ueland PM, Nesthus I, et al. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia. J Clin Jnvest 1996; 98: 2174-83.
18. Kluijtmans LA, Young IS, Boreham CA, et al. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood 2003; 101: 2483-8.
19. Willis L, Mehta MM. Studies in "pernicias anaemia" of pregnancy, I preliminary report. Indian Journal of Medical Research 1930; 17: 777-15.
20. Willis L. Treatment of "pernicias anaemia of pregnancy" and "tropical anaemia" with special reference to yeast extract as curative agent. Br Med J 1931; 1: 1059-63.
21. Angier RB, Boothe JH, Hutchings BL, et al. Synthesis of a compound identical with the L. casei factor isolated from liver. Science 1945; 102: 227-30.
22. Feldkamp M, Friedrichs M, Carey JC. Decreasing prevalence of neural tube defects in Utah, 1985-2000. Teratology 2002; 66 S.1: S23-8.
23. Persad VL, Van den Ho/MC, Dubé IM, et al. Incidence of open neural tube defects in Nova Scotia after folic acid fortification. CMAI 2002; 167: 241-6
24. Ray JG, Meier C, Vermeulen MJ, Boss S, et al. Association of neural tube defects and folic acid food fortification in Canada. Lancet 2002; 360: 2047-8.
25. Erickson JD. Folic acid and prevention of spina bifida and anencephaly. 10 years after the U.S. Public Health Service recommendation. MMWR Recomm Rep 2002; 51: 1-3.
26. Wilson RD, Davies G, Desilets V, et al. The use of folic acid for the prevention of neural tube defects and other congenital anomalies. Genetics Committee and Executive and Council of the Society of Obstetricians and Gynaecologists of Canada. J Obstet Gynaecol Can 2003; 25: 959-73.
27. MMWR Morb Mortal Wkly Rep. Knowledge and use of folic acid among women of reproductive age - Michigan, 1998. 2001 Mar 16; 50: 185-9.
28. Hankey CI, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999; 354: 407-15.
29. Torres OA, Miller VS, Buist NM, Hyland K. Folinic acid-responsive neonatal seizures. J Child Neurol. 1999; 14: 529-32.
30. Taylor MJ, Carney S, Geddes J, Goodwin G. Folate for depressive disorders. Cochrane Database Syst Rev 2003; (2): CD003390.
31. Malouf R, Grimley Evans J, Areosa Sastre A. Folic acid with or without vitamin B12 for cognition and dementia. Cochrane Database Syst Rev 2003; 4: CD0045 14.
32. Green R, Miller JW. Folate deficiency beyond megaloblastic anemia: hyperhomocysteinemia and other manifestations of dysfunctional folate status. Seminars in Hematology 1999; 36: 47-51.
33. Giovannucci E.: Epidemiologic studies of folate and colorectal neoplasia. A review. J Nutr 2002; 132: 2350-5.
34. Coppola A, Di Mimmo G. L'uso farmacologico dei folati: prospettive attuali. Riv It Ost Gin 2004; 1: 21-25.
35. Davì G, Di Minno G, Coppola A, et al. Oxidative stress and platelet activation in homozygous homocystinuria. Circulation 2001; 104: 1124-28.
36. Coppola A, Davì G, De Stefano V, et al. Homocysteine, coagulation, platelet fiinction and thrombosis. Semin Thromb Hemost 2000; 26.243-54.
37. Welch CN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042-50.
38. Jin L, Abou-Mohamed G, Caldwell RB, Caldwell RW. Endothelial cell dysfunction in a model of oxidative stress. Med Sci Monit 2001; 7: 585-91.
39. Weiss N, Heydrick SJ, Postea O, et al. Influence of hyperhomocysteinemia on the cellular redox state-impact on homocysteine-induced endothelial dysfunction. Clin Chem Lab Med 2003; 41: 1455-61.
40. Tsen CM, Hsieh CC, Yen CH, Lau YT. Homocysteine altered ROS generation and NO accumulation in endothelial cells. Chin J Physiol 2003; 46: 129-36.
41. Covers R, Rabelink TJ. Cellular regulation of endothelial nitric oxide synthase. Am J Physiol Renal Physiol 2001; 280: 193-6.
42. Verhaar MC, Stroes E, Rabelink TJ. Folates and Cardiovascular Disease. Arterioscler Thromb Vasc Biol 2002; 22: 6-13.
43. Ferretti G, Bacchetti T, Marotti E, Curatola G. Effect of homocysteinylation on human high-density lipoproteins: a correlation with paraoxonase activity. Metabolism 2003; 52: 146-51.
44. Ferretti G, Bacchetti T, Moroni C, et al. Effect of homocysteinylation of low density lipoproteins on lipid peroxidation of human endothelial cells. J Cell Biochem 2004; 92: 51-60.
45. Cianciolo C, Manna C, Isola E, et al. Effects of 5-MTHF therapy on hyperhomocysteinemia in dialysis patients. Nephrol Dial Transplant 2000; 15: 9-13.
46. Buccianti C, Raselli S, Baragetti I, et al. 5- methyltetrahydrofolate restores endothelial function in uraemic patients on convective haemodialysis. Nephrol Dial Transplant 2002; 17: 857-61.
47. Assanelli D, Bonanome A, Pezzini A, et al. Folic acid and Vitamin E supplementation effects on homocysteinemia, endothelial function and plasma antioxidant capacity in young myocardial infarction patients. Pharmacol Res 2004; 49: 79-84.
48. Stroes ESG, van Faassen EE, Yo M, et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res 2000; 86: 1129-34.
49. Verhaar MC, Wevwr RMR Kastelein JJP, et al. 5- methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 1998; 97: 237-41.
50. Doshi SN, McDowell FW, Moat SJ, et al. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation 2002; 105: 22-6.
51. Das UN. Folic acid says No to vascular diseases. Nutrition 2003; 19: 686-90.
52. Hyndman ME, Verma S, Rosenfeld RJ. Interaction of 5-methytertahydrofolate and tetrahydrobiopterin on endothelial function. Am J Physiol Heart Circ Physiol 2002; 282: 2167-72.
53. Reazk BM, Haenen CR, van der Vijgh WJ, Bast A. Tetrahydrofolate and 5-methyltetrahydrofolate are folates with high antioxidant activity. Identification of the antioxidant pharmacophore. FEBS Lett 2003; 555: 601-5.
54. Coppola A, Mazzola C, Fermo I, et al. Homocysteine-lowering effects and reduction of oxidative stress by 5-methyltetrahydrofolate (Prefolic) in subjects with 677TT methylenetetrahydrofolate reductase (MTHFR) genotype. J Inherit Metab Dis 2003; 26 (S1): 123-7.
55. Santi R, Demicheli M, Contino L, et al. Homocysteine plasma levels after suspension of vitamin treatment. J Thromb Haemost 2003; 1: 1330-4.
56. Saban-Ruiz J, Bajo-Martinez A, Bernai Morell E, et al. Is it possible to manage hyperhomocysteinemia with an intermittent therapy? Preliminaiy results. J Inherit Metab Dis 2003; 26 (S1): 118-22.
57. Lucock M. Is folic acid the ultimate functional food component for disease prevention? BMJ 2004; 328: 211-214.
58. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA 1997; 277: 1775-81.
59. Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-6.
60. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-55.
61. Egerton W, Silberberg J, Crooks R, Ray C, Lijuan X, Dudman N. Serial measures of plasma homocysteine after acute myocardial infarction. Am J Cardiol 1996; 77: 759-61.
62. Howard VJ, Sides EG, Newman GC, Cohen SN, Howard G, Malinow MR, Toole JF. Changes in plasma homocysteine in the acute phase after stroke. Stroke 2002; 33: 473-8.
63. Chambers JC, McGregor A, Jean-Marie J, Obeid OA, Kooner JS. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation 1999; 99: 1156-60.
64. Fryer R, Wilson B, Gubler D, Fitzgerald L, Rodgers G. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb Vasc Biol 1993; 13: 1327-33.
65. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002; 17/24: 3144-3421.
66. McKay DL, Perrone G, Rasmussen H, Dallal G, Blumberg JB. Multivitamin/mineral supplementation improves plasma B-vitamin status and homocysteine concentration in healthy older adults consuming a folate-fortified diet. J Nutr 2000; 130: 3090-6.
67. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998; 316: 894-8.
68. Boushey CJ, Beresford SA, Omen GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
69. Quinlivan EP, McPartlin J, McNulty H, et al. Importance of both folic acid and vitamin B12 in reduction of risk of vascular disease. Lancet 2002; 359: 227-8.
70. Bailey LB, Duhaney RL, Maneval DR, et al. Vitamin B12 status is inversely associated with plasma homocysteine in young women with C677T and/or A1298C methylenetetrahydrofolate reductase polymorphisms. J Nutr 2002; 132: 1872-8.
71. Quinlivan EP, Gregory JF.: Effect of food fortification on folic acid intake in the United States. AJCN 2003; 77: 221-225.
72. Malouf R, Grimley Evans J, Areosa Sastre A. Folic acid with or without vitamin B12 for cognition and dementia. Cochrane Database Syst Rev 2003; 4: CD0045 14.
73. Morris MS. Homocysteine and Alzheimer's disease. Lancet Neurol 2003; 2: 425-8.
74. Sachdev P. Homocysteine and neuropsychiatric disorders. Rev Bras Psiquiatr 2004; 26: 50-6.
75. Bailey LB. Folate, Methyl-Related Nutrients, Alcohol, and the MTHFR 677CT Polymorphism Affect Cancer Risk: Intake Recommendations. Supplement: International Research Conference on Food, Nutrition and Cancer. J Nutr 2003; 133: 3748S-53S
76. Eikelboom JW, Lonn E, Genest J Jr, et al. Homocysteine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999; 131: 363-75.
77. Ueland PM, Refsum H, Beresford SAA, et al. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000; 72: 324-8.
78. Van Dijk, RAJM, Rauwerda JA, Steyn M, et al. Long term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with a decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilatation or carotid artery stiffness. Arterioscler Thromb Vasc Biol 2001; 21: 2072-8.